Trump expands TrumpRx to 600 medicines as drug price pressure grows

TrumpRx's new generic aisle enters a market where the cheapest cash price is already a moving target. TrumpRx lists simvastatin at $6.19, GoodRx shows simvastatin from $10.80 with an average retail price of $64.89, and Amazon Pharmacy's simvastatin 20 mg search result shows a 30-day supply at $10.40 without insurance. On Mark Cuban's Cost Plus side, a recent review put atorvastatin 40 mg at $6.15, metformin 500 mg at $5.32 and levothyroxine 50 mcg at $5.91, while GoodRx listed levothyroxine from $9.90 with a $34.69 average retail price. That pattern suggests the biggest gains still go to uninsured patients and high-deductible plan members who are already paying cash and comparing line by line, while people with stronger coverage will still need to check copays first.

The White House said the expansion brought more than 600 generic medications onto TrumpRx.gov, including atorvastatin, clopidogrel, lisinopril and metformin. Generic discounts will be listed separately from the branded-drug deals negotiated through the administration's Most-Favored-Nation program, and the site will also fold in discounts from Amazon Pharmacy, Cost Plus Drugs and GoodRx. Controlled substances, drugs subject to FDA risk evaluation and mitigation strategies, and medicines not commonly sold direct to consumers will stay off the site.

The rollout put unusual competitors in the same room. Mark Cuban, Amazon Pharmacy vice president Tanvi Patel and GoodRx chief revenue officer Aaron Crittenden attended the White House event in Washington, D.C., as Trump pitched TrumpRx as a single place to find the lowest prescription cost. The administration has spent months trying to turn that claim into a larger pricing strategy, building MFN deals with manufacturers while using TrumpRx as a storefront for cash shoppers.

The administration said TrumpRx has drawn more than 10 million visits and saved Americans more than $400 million since launching on February 5, 2026. In April, the White House said Trump had signed his 17th MFN deal, covering 17 leading manufacturers and 86% of the branded drug market. Even with those deals, the new generic push makes clear that drug affordability remains a household problem, not just a political talking point, because the savings depend on whether a patient has insurance, a deductible, Medicare coverage or no coverage at all.